Table 1.
Age (yrs) | Total | Total (%) | Live birth | Cumulative LBR (%) |
---|---|---|---|---|
<30 | 68 | 21.9% | 18 | 26.5% |
30 – <35 | 112 | 36.1% | 26 | 23.2% |
35 – <38 | 49 | 15.8% | 13 | 26.5% |
38 – <40 | 37 | 11.9% | 5 | 13.5% |
>= 40 | 44 | 14.2% | 1 | 2.3% |
Cumulative Total | 310 | 63 | 20.3% | |
TMC (mil) | Per Cycle LBR (%) | |||
0 – <2 | 28 | 4.3% | 0 | 0.0% |
2 – <6 | 59 | 9.0% | 3 | 5.1% |
6 – <ll | 92 | 14.0% | 8 | 8.7% |
11 – <16 | 71 | 10.8% | 5 | 7.0% |
16 – <21 | 64 | 9.8% | 8 | 12.5% |
>= 21 | 341 | 52.1% | 39 | 11.4% |
Total by cycle | 655 | 63 | 9.6% | |
Etiologya | Per Cycle LBR (%) | |||
Male factor | 108 | 30.1% | 26 | 24.1% |
Ovulatory dysfunction | 94 | 26.2% | 27 | 28.7% |
Unexplained | 74 | 20.6% | 8 | 10.8% |
Tubal factor | 21 | 5.8% | 1 | 4.8% |
Endometriosis | 20 | 5.6% | 3 | 15.0% |
Uterine anomaly | 19 | 5.3% | 1 | 5.3% |
Recurrent pregnancy loss | 19 | 5.3% | 2 | 10.5% |
Other | 4 | 1.1% | 0 | 0.0% |
a50 of the 310 couples with more than one etiology | ||||
Treatment | Per Cycle LBR (%) | |||
Clomiphene Citrate (CC) | 424 | 64.7% | 37 | 8.7% |
CC + Gonadotropins | 30 | 4.6% | 7 | 23.3% |
Letrozole | 90 | 13.7% | 7 | 7.8% |
Letrozole + Gonadotropins | 11 | 1.7% | 1 | 9.1% |
Gonadotropins | 58 | 8.9% | 8 | 13.8% |
Natural cycle | 42 | 6.4% | 3 | 7.1% |
Ovulatory monitoring | Per Cycle LBR (%) | |||
Ovulation predictor kit | 468 | 71.5% | 45 | 9.6% |
Recombinant bHCG | 187 | 28.5% | 18 | 9.6% |
Sperm preparation | Per Cycle LBR (%) | |||
Fresh | 529 | 80.8% | 49 | 9.3% |
Frozen | 126 | 19.2% | 14 | 11.1% |